Manufacturing

How Will AI and Robotics Transform Metallurgy?
Tech & Innovation How Will AI and Robotics Transform Metallurgy?

The traditional image of a metallurgist surrounded by roaring furnaces and manual measuring tools has been rapidly superseded by a high-tech reality where silicon-based intelligence directs the assembly of novel atomic structures. Texas A&M University’s ARM-MIP initiative represents a pivotal

How Will Teledyne’s Varex Acquisition Reshape Imaging?
Management & Regulatory How Will Teledyne’s Varex Acquisition Reshape Imaging?

Teledyne’s long-term mergers and acquisitions strategy has culminated in the purchase of Varex, completing a decade-long effort to dominate every link in the digital imaging chain. For many years, the imaging sector has been a patchwork of specialized providers, where medical and industrial giants

Can Off-the-Shelf CAR T Therapy Prevent Lymphoma Relapse?
Research & Development Can Off-the-Shelf CAR T Therapy Prevent Lymphoma Relapse?

Detecting minimal residual disease through high-sensitivity blood tests allows clinicians to identify high-risk patients who might benefit from immediate cellular therapy despite appearing to be in remission. This shift toward early intervention represents a departure from traditional

Hims & Hers Enters the Unproven Longevity Peptide Market
Management & Regulatory Hims & Hers Enters the Unproven Longevity Peptide Market

The telehealth industry is currently navigating a complex regulatory landscape as the FDA prepares to finalize rules regarding which specific peptides, such as BPC-157, can be legally compounded. This pivot occurs as Hims & Hers Health, Inc. aggressively shifts its focus toward the burgeoning

How Will the Again-Geno Deal Revolutionize Biomanufacturing?
Management & Regulatory How Will the Again-Geno Deal Revolutionize Biomanufacturing?

The industrial landscape is currently undergoing a seismic shift as the acquisition of Genomatica by the Danish innovator Again creates a formidable powerhouse capable of redefining the boundaries of sustainable chemical production. This merger represents more than just a corporate expansion; it is

Can the CPHI Summit Close the Sustainability Gap in Pharma?
Management & Regulatory Can the CPHI Summit Close the Sustainability Gap in Pharma?

The shift in the pharmaceutical landscape has reached a point where environmental stewardship is no longer an optional component of corporate social responsibility. For decades, the global pharmaceutical sector operated under the assumption that life-saving patient outcomes justified a heavy

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later